Tivic Health Rebrands as Valion Bio, Sharpening Biopharma Focus

Tivic Health Systems ( (TIVC) ) has shared an announcement.

Valion Bio, formerly Tivic Health Systems, is a late-stage biopharmaceutical company focused on biologics that modulate innate immunity, led by Entolimod as both a radiation medical countermeasure and an oncology supportive care candidate. Its operations are reinforced by Velocity Bioworks, a wholly owned CDMO acquired in December 2025 to provide in-house biomanufacturing capacity and third-party services for early-stage biologics.

On April 22, 2026, the company filed to change its corporate name to Valion Bio, Inc., with the new name and ticker VBIO taking effect on Nasdaq on April 28, 2026, marking the formal completion of its shift away from consumer medical devices toward a government-aligned, late-stage biopharma model. The rebrand, supported by leadership with prior experience advancing Entolimod and by strategic positioning near U.S. defense and biodefense hubs, highlights a business now centered on potential government stockpile procurement and diversified CDMO revenues, with implications for investors seeking exposure to national preparedness and oncology markets.

Valion Bio’s integration of a government-priority drug candidate, domestic manufacturing capability, and location within a key biodefense ecosystem underscores its effort to strengthen supply chain security and align with federal biomanufacturing and national stockpile priorities. This positioning, combined with CDMO income potential from Velocity Bioworks, could reduce reliance on equity financing and reshape the company’s risk profile for shareholders and partners as it advances its late-stage pipeline.

Spark’s Take on TIVC Stock

According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.

The score is held down primarily by very weak financial performance (shrinking revenue, heavy losses, and cash burn with capital-base erosion). Technical indicators are moderately supportive and the biopharma pivot progress provides some upside narrative, but valuation is constrained by losses and corporate events add listing-risk overhang.

To see Spark’s full report on TIVC stock, click here.

More about Tivic Health Systems

Valion Bio, formerly Tivic Health Systems, is a late-stage biopharmaceutical company developing biologic drugs that activate innate immune pathways for cytoprotection and immune modulation. Its portfolio is led by Entolimod, a TLR5 agonist with FDA Fast Track and Orphan Drug designations, alongside next-generation candidate Entolasta and a wholly owned CDMO unit, Velocity Bioworks.

The company targets dual markets in national medical countermeasures and oncology supportive care, including chemotherapy-induced neutropenia. Velocity Bioworks underpins Valion Bio’s internal manufacturing and pursues third-party CDMO business, focusing on early-stage biologics production to create diversified and potentially non-dilutive revenue streams.

Average Trading Volume: 215,850

Technical Sentiment Signal: Sell

Current Market Cap: $3.34M

For detailed information about TIVC stock, go to TipRanks’ Stock Analysis page.